UK markets closed
Explore/

Biotech and drug stocks

Biotech and drug stocks

7.41k followers31 symbols Watchlist by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies.

Curated by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.

The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.

This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.

Background

Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.

Performance

WatchlistChange today1-month return1-year returnTotal return
Biotech and drug stocks-0.49%---
^GSPC+0.11%+3.10%+30.45%+5549.84%

31 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
LLYEli Lilly and Company777.96-0.22-0.03%16:00 GMT-43.19M3.24M739.66B
NVONovo Nordisk A/S128.4+0.35+0.27%16:00 GMT-43.50M5.23M572.92B
JNJJohnson & Johnson158.19+0.23+0.15%16:00 GMT-46.07M7.16M381.20B
MRKMerck & Co., Inc.131.95+0.20+0.15%16:00 GMT-410.13M8.81M334.18B
ABBVAbbVie Inc.182.1+1.75+0.97%16:00 GMT-45.40M5.71M322.44B
AZNAstraZeneca PLC67.75-0.51-0.75%16:00 GMT-43.42M6.34M210.05B
RHHBYRoche Holding AG31.92+0.61+1.95%16:00 GMT-41.77M1.83M205.51B
NVSNovartis AG96.73+0.85+0.89%16:00 GMT-41.51M1.45M197.72B
PFEPfizer Inc.27.75-0.03-0.11%16:00 GMT-439.96M43.83M157.14B
AMGNAmgen Inc.284.32-1.98-0.69%16:00 GMT-42.28M3.04M152.37B
SNYSanofi48.6-0.94-1.90%16:00 GMT-42.41M1.86M124.09B
BMYBristol-Myers Squibb Company54.23+0.98+1.84%16:00 GMT-413.54M16.87M109.66B
VRTXVertex Pharmaceuticals Incorporated418.01+0.69+0.17%16:00 GMT-41.05M1.32M107.98B
REGNRegeneron Pharmaceuticals, Inc.962.49-3.81-0.39%16:00 GMT-4446.66k502.13k105.64B
GILDGilead Sciences, Inc.73.25+0.24+0.33%16:00 GMT-48.24M7.61M91.25B
GSKGlaxoSmithKline plc42.87-0.12-0.28%16:00 GMT-41.85M3.57M87.98B
ZTSZoetis Inc.169.21+0.70+0.42%16:00 GMT-43.34M2.74M77.48B
TAKTakeda Pharmaceutical Company Limited13.89-0.30-2.11%16:00 GMT-41.48M1.85M43.58B
MRNAModerna, Inc.106.56-4.03-3.64%16:00 GMT-43.96M4.41M40.80B
HLNHaleon plc8.49-0.04-0.47%16:00 GMT-44.37M5.56M38.77B
BIIBBiogen Inc.215.63-0.71-0.33%16:00 GMT-41.76M1.18M31.34B
BAYRYBayer Aktiengesellschaft7.66-0.01-0.13%15:59 GMT-43.57M1.77M30.24B
ARGXargenx SE393.72-4.87-1.22%16:00 GMT-4184.20k349.80k23.35B
BNTXBioNTech SE92.25-0.72-0.77%16:00 GMT-4432.99k692.25k21.93B
GMABGenmab A/S29.91-0.72-2.35%16:00 GMT-4355.48k642.34k19.71B
ALPMYAstellas Pharma Inc.10.75-0.19-1.74%15:59 GMT-4295.56k251.19k19.27B
ALNYAlnylam Pharmaceuticals, Inc.149.45-4.94-3.20%16:00 GMT-4554.94k869.85k18.82B
RPRXRoyalty Pharma plc30.37-0.08-0.26%16:00 GMT-42.71M2.68M18.14B
BGNEBeiGene, Ltd.156.39+1.31+0.84%16:00 GMT-4104.13k283.42k16.96B
BMRNBioMarin Pharmaceutical Inc.87.34-1.27-1.43%16:00 GMT-4928.41k1.33M16.48B
  • Insider Monkey

    Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

    TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]

  • Reuters

    Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

    Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. Novo Nordisk's popular obesity drug Wegovy and Eli Lilly's in demand Zepbound are GLP-1 drugs. Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.

  • TheStreet

    Morningstar unveils 10 cheap stocks with big moats

    Analysts' stock picks include retail, consumer, and healthcare stocks.